Cancer Breast Cancer

Publication Date	March 2008
Publisher	Life Science Analytics
Product Type	Report
Pages	395
ISBN Number	not applicable
Product Code	LSA02283

Price

£800.00
approximately: $1,169 | €877

PDF

PRINT £850 ($1,242 | €932)

Order above formats by FAX

Summary

Life Science Analytics', Cancer Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics' Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
Keep track of your competitors and partners by better understanding their product pipeline.
Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
Maintain a critical competitive advantage.

Content

Recent Highlights and Changes
Upcoming Patent Expires by Therapy Area
- Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Pipeline Overview
  - % of Projects (by Phase of Development)
  - No. of Projects by Phase of Development
  - Marketed Products vs. Pipeline Products
- Company Overview - Pipeline Projects
  - Company Overview - Pipeline Projects
  - Top Companies in late stage Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Projects
  - Biogen Idec Inc
  - Ascenta Therapeutics, Inc.
  - Celgene Corporation
  - Bristol-Myers Squibb Company
  - Cephalon Inc
  - Cell Genesys Inc
  - Genmab A/S
  - Genentech Inc
  - Genzyme Corporation
  - Genta Incorporated
  - Johnson & Johnson
  - Geron Corporation
  - MethylGene Inc
  - Merck & Co Inc
  - Taiho Pharmaceutical Co., Ltd.
  - Mundipharma International Limited
  - Vertex Pharmaceuticals Inc
  - Topotarget A/S
  - Xanthus Pharmaceuticals, Inc.
  - erly Xanthus Life Sciences)
  - Vion Pharmaceuticals Inc
  - Top Companies in early stage Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Projects
  - Affimed Therapeutics AG
  - Aegera Therapeutics Inc.
  - Amgen Inc
  - Alexion Pharmaceuticals Inc
  - Ariad Pharmaceuticals Inc
  - AquaGenyx Pharmaceuticals Inc.
  - Biogen Idec Inc
  - AstraZeneca Plc
  - CSL Limited
  - Callisto Pharmaceuticals Inc
  - Genentech Inc
  - EntreMed Inc
  - MAT Biopharma
  - Innovive Pharmaceuticals, Inc.
  - Onconova Therapeutics Inc.
  - Novartis AG
  - Sanofi-Aventis
  - Reata Pharmaceuticals, Inc.
  - Targa Therapeutics Corp.
  - Sunesis Pharmaceuticals Inc
- Pipeline Revenue
  - Pipeline Revenue
- Full Pipeline View
  - Pre Clinical Pipeline View
  - Phase I Pipeline View
  - Phase II Pipeline View
  - Phase III Pipeline View
  - Pending Approval Pipeline View
  - Approved Pipeline View
  - on the Market Pipeline View
  - Discovery/Development Pipeline View